Developer of Cold-EEZE® - clinically proven to shorten duration of common colds
ProPhase Labs researches, develops, manufactures, distributes, and markets over-the-counter (OTC) cold remedy and consumer products, natural base health products, and other supplements and cosmeceuticals in the United States.
Its OTC offerings include Cold-EEZE®, a zinc gluconate glycine product to reduce the duration and severity of the common cold symptoms; Kids-EEZE® soft chews to treat chest congestion, cough/cold, or allergies; and Organix® Complete cough/cold drops for coughs & sore throats due to colds.
The Company sells its consumer health products through national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores, and pharmacies.
ProPhase Labs has a joint venture with Phusion Laboratories, LLC for the development and commercialization of non-prescription remedies using patented TPM technology. It also manufactures private label lozenges for retail customers; and manufactures, markets, and distributes a range of homeopathic and health products.
The CHEAP Investor Subscription-Based Newsletter has highlighted ProPhase Labs several times, and the stock has been a profitable investment for our subscribers in the past. Our last profile was in the December issue at $0.87, and it soared 83% to a high of $1.59. Since the price has fallen back near the $1 level, we thought it was time to take another look at ProPhase:
In November 2005, the stock (called Quigley back then) was a Wall Street favorite, selling at $16.80, when its major product, ColdEEZE, was a hot new product.
The Company has a good balance sheet with $4.6 million ($0.32 per share) in cash, a book value of $0.87 per share and no debt. Insiders own approximately 44% of the 14.6 million total shares outstanding, and institutions own 6% of the float (shares in public hands). This past quarter, insiders have purchased 300,000 shares at prices ranging between $0.85 and $0.95.
For the year ended December 31, 2011 revenues were up 20% to $17.5 million and net loss of $2.7 million was down from a loss of $3.6 million a year ago. There are only a total of 14.6 million shares outstanding.
Ted Karkus Chairman and CEO states, "Our success in building revenues in fiscal 2011 demonstrates that we now have a stronger distribution platform to launch new products and applications. In August 2011 we launched Cold-EEZE® Oral Spray which provides the same active ingredients for shortening the duration of the common cold as our clinically proven Cold-EEZE® lozenges, but in a new and convenient delivery system. This introduction was a natural next step in our evolution as a Company and at the core of our strategy to provide additional cold relief products for our loyal consumers that leverages our flagship Cold-EEZE® brand and adds incremental revenues for our Company. Initial retail and consumer response to our Cold-EEZE® Oral Spray is encouraging. We also hope to launch an additional Cold-EEZE® branded cold remedy product in the third quarter of fiscal 2012."
CONCLUSION
With a market cap of only $15 million and a very well-known product line, ProPhase could be an acquisition candidate. In our opinion, we believe the stock has long-term potential. To Continue researching ProPhase Labs, Inc., 621 North Shady Retreat Road, Doylestown, Pennsylvania 18901 or call 215-345-0919. The fax number is 215-345-5920. The Website:http://www.prophaselabs.com.
FULL DISCLOSURE
The CHEAP Investor has NOT BEEN COMPENSATED in anyway for this profile of (NASDAQ:PRPH) ProPhase Labs, Inc. and has chosen to profile this company based on the merits and fundamentals of the company. To the best of our knowledge, neither Mathews and Associates Inc., any of it's employees or any associate in connection with the distribution of this material own any shares and Hold No Position in (NASDAQ:PRPH) that could benefit as a result of this disseminated information.
Bill Mathews, the Editor of The CHEAP Investor, has been a long-term shareholder of (NASDAQ:PRPH) ProPhase Labs, Inc. and currently holds a position of 8,300 shares in his family portfolio which he has committed to hold and Will Not Sell for a Minimum Period of 90 Days following the release of this profile.
Recent PRPH News
- PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- ProPhase Labs Unveils Project ZenQ-AI • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024 • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 01:00:00 AM
- ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024 • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:49 PM
- ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:05:18 PM
- ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024 • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:04:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:00:39 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output. • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- DSS Inc. Issues Letter to Shareholders • GlobeNewswire Inc. • 10/12/2023 12:25:00 PM
- ProPhase Labs to Present at The ThinkEquity Conference • GlobeNewswire Inc. • 10/12/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:10:43 PM
- ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call. • GlobeNewswire Inc. • 08/10/2023 02:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:00:15 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/10/2023 12:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM